TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07542704: A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB368 in Participants With Advanced Solid Malignancies With KRAS G12S

Sponsor: Kumquat Biosciences Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 48 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT07542704 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07542704 Rescue Dossier →